Cantourage Group SEHAM:HIGH -5.83%20 EBIT per Share is €0.00 as of Jun. 2025. GuruFocus rates HAM:HIGH with a GF Score™ of 20/100. The stock has 4 warning signs investors should review. Among 811 Drug Manufacturers companies, Cantourage Group SE ranks worse than 98.64% on this metric.
Cantourage Group SE's EBIT per Share for the
six
months ended in Jun. 2025 was €0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2025 was €0.00.
During the past 3 years, the average EBIT per Share Growth Rate was -94.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Cantourage Group SE's EBIT per Share or its related term are showing as below:
HAM:HIGH'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -94.7 Med: -94.7 Max: -94.7
Current: -94.7
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Cantourage Group SE was -94.70% per year. The lowest was -94.70% per year. And the median was -94.70% per year.
HAM:HIGH's 3-Year EBIT Growth Rate is ranked worse than 98.64% of 811
companies
in the Drug Manufacturers industry
Industry Median: 7.8
vs HAM:HIGH: -94.70
Cantourage Group SE (HAM:HIGH) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Cantourage Group SE EBIT per Share Related Terms
Cantourage Group SE EBIT per Share Historical Data
* Premium members only.
The historical data trend for Cantourage Group SE's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cantourage Group SE (HAM:HIGH) has a EBIT per Share of €0.00 as of Jun. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Cantourage Group SE and its competitors. According to the industry distribution chart, Cantourage Group SE ranks #800 out of 811 companies in the Drug Manufacturers industry, placing it in the top 98.6%.
Is Cantourage Group SE's EBIT per Share too high?
Cantourage Group SE's current EBIT per Share is €0.00. Based on the distribution chart, Cantourage Group SE ranks #800 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cantourage Group SE has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Cantourage Group SE's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cantourage Group SE ranks #800 out of 811 companies for EBIT per Share. This places Cantourage Group SE in the lower half of its industry. The industry median EBIT per Share is 7.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Cantourage Group SE and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cantourage Group SE's current EBIT per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantourage Group SE stock overvalued right now?
Cantourage Group SE (HAM:HIGH) has a current EBIT per Share of €0.00. The current EBIT per Share is €0.00. Cantourage Group SE's overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Cantourage Group SE (HAM:HIGH), the current EBIT per Share is €0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cantourage Group SE is engaged in the manufacture and wholesale of medicinal preparations based on cannabis and the trade and distribution of other legally permissible cannabis products, medical devices, pharmaceuticals, and accessories. The group offers cannabis flowers, dronabinol, CBD, and extracts of various strains.
20GF Score
Get the complete analysis for HAM:HIGH
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:HIGH has been successfully added to your 
